Status | Study |
Not yet recruiting |
Study Name: Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept Condition: Retinal Vein Occlusion Date: 2016-08-23 |
Recruiting |
Study Name: Study of Retinal Oxygenation in Central Retinal Vein Occlusion Condition: Retinal Vein Occlusion Date: 2015-08-07 |
Completed |
Study Name: Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Date: 2014-01-02 Interventions: Drug: Lucentis intravitreal injection |
Completed |
Study Name: OCT in Retinal Vein Occlusions Condition: Retinal Vein Occlusions Date: 2013-11-19 |
Completed |
Study Name: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Condition: Central Retinal Vein Occlusion Date: 2013-10-18 Interventions: Other: Sham injection Sham inj |
Active, not recruiting |
Study Name: Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) Condition: Retinal Vein Occlusion Date: 2013-06-10 |
Completed |
Study Name: Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Condition: Retinal Vein Occlusion Date: 2013-02-08 Interventions: Drug: dexamethasone implant Other Name: Ozurdex |
Recruiting |
Study Name: Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Condition: Retinal Vein Occlusion Date: 2012-06-28 Interventions: Drug: Bevacizumab 1.25 mg beva |
Completed |
Study Name: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Condition: Branch Retinal Vein Occlusion Date: 2012-05-02 Interventions: Drug: Ranibizumab Other Name: |
Completed |
Study Name: Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion Condition: Central Retinal Vein Occlusion Date: 2012-04-12 Interventions: Drug: Tissue Plasminogen Activator Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes follow |